To support our claim, we validated the expression of LXR-α and FXR and their target genes in both in vitro and in vivo NAFLD models treated with withaferin A. Along with withaferin A, we used the LXR-α specific agonist 25-hydroxycholesterol (25HC) and the FXR-specific agonist taurochenodeoxycholate (TCDC) and TGR5 (bile acid membrane receptor)-specific agonist deoxycholic acid (DCA). The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatotic liver disease.